Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response
Al-kaabi, M.M.; Alshareeda, A.T.; Jerjees, D.A.; Muftah, A.A.; Green, A.R.; Alsubhi, N.H.; Nolan, C.C.; Chan, S.; Cornford, E.; Madhusudan, S.; Ellis, I.O.; Rakha, E.A.
ANDREW GREEN firstname.lastname@example.org
SRINIVASAN MADHUSUDAN email@example.com
Professor of Medical Oncology
Professor IAN ELLIS IAN.ELLIS@NOTTINGHAM.AC.UK
Professor of Cancer Pathology
EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology
Checkpoint kinase1 (CHK1), which is a key component of DNA-damage-activated checkpoint signalling response, may have a role in breast cancer (BC) pathogenesis and influence response to chemotherapy. This study investigated the clinicopathological significance of phosphorylated CHK1 (pCHK1) protein in BC.
pCHK1 protein expression was assessed using immunohistochemistry in a large, well-characterized annotated series of early-stage primary operable invasive BC prepared as tissue microarray (n=1200).
pCHK1 showed nuclear and/or cytoplasmic expression. Tumours with nuclear expression showed positive associations with favourable prognostic features such as lower grade, lower mitotic activity, expression of hormone receptor and lack of expression of KI67 and PI3K (P
Al-kaabi, M., Alshareeda, A., Jerjees, D., Muftah, A., Green, A., Alsubhi, N., …Rakha, E. (2015). Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. British Journal of Cancer, 112(5), 901-911. https://doi.org/10.1038/bjc.2014.576
|Journal Article Type||Article|
|Acceptance Date||Sep 23, 2014|
|Online Publication Date||Feb 17, 2015|
|Deposit Date||Oct 17, 2018|
|Publicly Available Date||Oct 17, 2018|
|Journal||British Journal of Cancer|
|Publisher||Cancer Research UK|
|Peer Reviewed||Peer Reviewed|
You might also like
Further evidence to support bimodality of oestrogen receptor expression in breast cancer